Skip to main content
. 2017 Jun 19;130(7):891–899. doi: 10.1182/blood-2017-05-781450

Figure 2.

Figure 2.

Effect of eculizumab (anti-C5) and ACH-4471 (a complement factor D inhibitor) on complement pathways. (A,C) CP activity measured by CP Wieslab. (B,D) CP activity measured by hemolytic assay. Horizontal dashed lines represent IC50, which was 18.3 µg/mL for eculizumab. (E) AP activity measured by AP Wieslab assay. At a concentration of 1 µM ACH-4471 (0.58 µg/mL), complete inhibition was achieved.